Background. Influenza A H1N1 and B are associated with neurological complications including seizures, encephalopathy and encephalitis. However, this season, when H3N2 was the predominant strain, many patients were admitted with neurological manifestations of influenza (NMI). The study objectives were to: 1) identify clinical characteristics of children with NMI and 2) compare demographics and clinical characteristics with influenza-positive controls.
Background. Peramivir (PVR) is a potent neuraminidase inhibitor with in vitro activity against all influenza virus subtypes. Previous studies demonstrated the efficacy and safety of PVR as a single dose intravenous (IV) treatment for acute uncomplicated influenza in adults.
Methods. A phase 3 study compared age-appropriate doses of single dose IV PVR to 5 days of oral oseltamivir (OSE) (4:1 randomization, stratified by age) in pediatric subjects age 0 -17 years within 48 hours of onset of acute uncomplicated influenza. Plasma concentrations of PVR were measured up to 6 hours post dose. Serial viral titers were measured from nasopharyngeal swabs. Severity of influenza signs and symptoms were recorded in a diary.
Results. 122 subjects were enrolled up to a data cutoff of March 31, 2017 (<2 yrs, n = 7; 2-<7yrs, n = 37; 7-<13 yrs, n = 48; 13-17 yrs, n = 30). Interim results are reported for the first 108 subjects randomized, of which 101 (94%) received study drug. Influenza was confirmed by PCR in 75 (74%) subjects who received study drug (Intentto-treat-Infected [ITTI] Conclusion. Treatment of influenza in pediatric subjects with single dose IV PVR or 5 days of oral OSE was generally safe and well tolerated. Whilst not powered for efficacy differences, trends were observed in more rapid reduction in virus shedding and symptom alleviation for PVR treated subjects compared with OSE. The study continues to enroll subjects < 7 years. Saturday, October 7, 2017: 12:30 PM Background. Almost all children are infected with RSV by 2 yrs of age, yet <3% are hospitalized. The immune response of children with mild RSV infection who do not develop severe disease is not fully understood. Characterization of such response may have implications for vaccine development. We sought to define the transcriptomic and cellular immune profiles associated with mild RSV disease in children.
Methods. We enrolled 190 previously healthy children <2 yrs of age: 125 with RSV infection treated as outpatients (OP; mild disease; n = 41) or inpatients (IP; severe disease; n = 84), and age-matched healthy controls (HC; n = 65). Nasopharyngeal RSV loads, blood RNA transcriptome and WBC immunophenotyping were analyzed according to disease severity.
Results. OP were older (7.6 m) than IP (2.6 m; P < 0.01). Median duration of symptoms at enrollment in both groups was 4 days, yet RSV loads were higher in OP vs. IP (5.5 log 10 and 4.9 log 10 copies/mL respectively; P = 0.05). To control for differences in age, transcriptional signatures were derived in an age-matched discovery cohort (OP n = 24; IP n = 24; HC n = 24) and subsequently validated in an independent validation cohort (n = 55). Compared with IP, the OP signature was characterized by greater activation of interferon (IFN) and plasma cell genes, less suppression of T-cell, and cytotoxic/NK cell genes and less activation of inflammation and neutrophil genes (P < 0.01; Fig 1) . Overall, plasma cell genes positively correlated with number of plasmablasts, plasma cells, and T follicular helper cells (r=0.6; P < .01), while IFN gene expression inversely correlated with T-cells, DC and B cells numbers (r=-0.4 P < .05). Neutrophil numbers correlated with neutrophil (r=0.5; P < =.02) and inflammation gene expression (r=0.8; P < 0.001). Last, monocyte numbers were higher in IP and OP vs. HC (P < 0.01) however; HLA-DR low monocytes were increased only in IP.
Conclusion. Children with mild disease demonstrated a distinct cellular and transcriptional immune response to RSV. Despite that RSV loads were higher in these children, IFN expression and monocyte activation were increased and T and NK cell genes less suppressed, suggesting that robust immune responses are associated with improved clinical outcomes in children with RSV infection. 
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